Fiocruz bank potential Cannabis and asks for regulation – 04/21/2023 – Cannabis Inc.

Fiocruz (Oswaldo Cruz Foundation) published, last Wednesday (19), a technical note endorsing the therapeutic potential of medicinal Cannabis. The effects of Cannabis derivatives, such as CBD (Cannabidiol, substance without psychoactive effect) and THC (Tetrahydrocannabidiol, with psychoactive effect), on some diseases have already been confirmed by a series of scientific studies, which are multiplying around the world.

The text is signed by Fiocruz’s Institutional Program of Drug Policies, Human Rights and Mental Health and informs that it has “the objective of providing subsidies based on the scientific literature for the institutions responsible for legislation, regulation, research, production, standardization, distribution and use from the cannabis and derivatives for therapeutic purposes in Brazil, as well as for society in general”.

According to the note, the objective is to contribute to “improving knowledge about the subject and to advancing access to treatments based on WAnnabis and derivatives. cannabis medicinal. The concern of the group of researchers is to establish public policies to train qualified professionals, stimulate the production of inputs for research. “We consider it crucial that Brazil position itself at the forefront of this process, investing decisively in national scientific production.”

The appeal comes at an important time when Congress is discussing the possibility of free distribution of cannabis by the SUS (Unified Health System) across the country. Currently, even the companies that obtain authorization from Anvisa to place the merchandise on the shelves of pharmacies, import the input. The country has the potential to produce oil on national soil, which would greatly reduce government spending.

proven indications

• Chronic pain – Different formulations containing cannabinoids significantly reduce pain in certain types of chronic pain. Dozens of randomized clinical trials submitted to meta-analyses have shown that pain reduction was greater in the group that received cannabinoids compared to the control group.
• Refractory epilepsy – a meta-analysis study with six randomized clinical trials showed a significant decrease in seizure frequencies in the group treated with cannabinoids compared to the control group. In general, the participants were resistant to the reference drugs and found cannabinoids to be an effective therapy to alleviate seizures.
• spasticity – more than a dozen randomized clinical trials have shown a significant effect of treatment with cannabinoids in reducing spasticity due to multiple sclerosis. Other symptoms associated with multiple sclerosis did not improve with the test treatment.
• Nausea, vomiting and loss of appetite – cannabinoids were effective in reducing nausea and vomiting linked to chemotherapy (a treatment that cancer patients undergo. Methodological limitations make the results still present a low level of confidence. A meta-analysis showed the effectiveness of cannabinoids in increasing appetite in comparison to control groups.
• neuropsychiatric disorders – such as Parkinson’s disease and sleep disorders, showed significant improvement in symptoms, with cannabinoid treatment versus control with a satisfactory level of evidence.

Indications with still unsatisfactory evidence

• Autistic Spectrum Disorder (ASD);
• Anticancer activity in certain tumor processes;
• Irritable bowel syndrome;
• Huntington’s disease;
• Amyotrophic lateral sclerosis;
• Rheumatoid arthritis;
• Metabolic and cardiovascular diseases;
• Tourette’s Syndrome;
• Dystonia;
• Insanity;
• Glaucoma,
• Psychiatric disorders, such as symptoms associated with anxiety, mood, psychotic, substance use, attention deficit hyperactivity disorder, post-traumatic stress disorder and bipolar affective disorders.

PRESENT LINK: Did you like this text? Subscriber can release five free hits of any link per day. Just click the blue F below.